Healthcare distributor and services company Cardinal Health (NYSE: CAH) fell short of the market’s revenue expectations in Q2 CY2026, but sales rose 5.8% year on year to $63.67 billion. Its non-GAAP profit of $2.60 per share was 7.4% above analysts’ consensus estimates.
Is now the time to buy CAH? Find out in our full research report (it’s free for active Edge members).
Cardinal Health (CAH) Q2 CY2026 Highlights:
- Revenue: $63.67 billion vs analyst estimates of $65.42 billion (5.8% year-on-year growth, 2.7% miss)
- Adjusted EPS: $2.60 vs analyst estimates of $2.42 (7.4% beat)
- Adjusted EPS guidance for the upcoming financial year 2027 is $12.50 at the midpoint, beating analyst estimates by 3.5%
- Operating Margin: 1.1%, in line with the same quarter last year
- Market Capitalization: $55.88 billion
StockStory’s Take
Cardinal Health’s second quarter results reflected strong profit growth, despite revenue falling short of Wall Street’s expectations. Management credited broad-based demand in its Pharmaceutical and Specialty Solutions segment, stable operating margins, and continued progress on its improvement plan in the Global Medical Products and Distribution unit as key performance drivers. CFO Aaron Alt called out “strong demand, strong execution, strong profit,” highlighting the company’s ability to deliver high service levels and operational resilience even as regulatory and input cost pressures persisted.
Looking toward the remainder of the year, management’s guidance is shaped by continued growth in specialty pharmaceuticals, targeted investments in automation and technology, and further scaling of its high-margin businesses. CEO Jason Hollar emphasized, “We are well positioned for growth and long-term value creation in fiscal '27 and beyond,” and outlined ongoing expansion in advanced therapies, home-based care, and logistics. The company also indicated that the adoption of new specialty services and recent acquisitions will support profit expansion, though management cautioned that headwinds from input costs and regulatory changes could temper the pace of improvement.
Key Insights from Management’s Remarks
Management attributed the quarter’s profit outperformance to robust specialty pharma growth, improving operational efficiency, and nonrecurring tariff refunds, while investments in automation and recent acquisitions laid the groundwork for future expansion.
- Specialty pharma growth: The Pharmaceutical and Specialty Solutions segment saw strong demand, especially in specialty pharmaceuticals and generics, with above-market growth in upstream and downstream services. Management noted robust momentum in areas like autoimmune, oncology, and gene therapy distribution.
- Operational efficiencies and automation: Investments in automation and technology across Cardinal Health’s distribution network improved order accuracy, employee safety, and enabled higher service levels, contributing to margin stability despite input cost pressures.
- Tariff refund windfall: The Global Medical Products and Distribution unit benefited from a one-time $100 million operating earnings boost related to IEEPA tariff refunds, which management stressed is not expected to recur in future quarters.
- Growth in at-Home and nuclear units: The at-Home Solutions business delivered double-digit profit growth, while the Nuclear & Precision Health Solutions business posted another quarter of impressive revenue growth, with its Theranostics and PET (positron emission tomography) services expanding rapidly, particularly for oncology and neurology.
- Disciplined capital allocation: The company continued to prioritize targeted investments and returned $1.35 billion to shareholders through share repurchases, while also announcing a $5 billion increase to its buyback authorization, taking total authorization to $6.4 billion. Management confirmed a new $4 billion revolving credit facility to support future flexibility.
Drivers of Future Performance
Cardinal Health expects future performance to be driven by solid specialty pharma demand, margin initiatives, and the ramp-up of recent acquisitions, though regulatory and cost headwinds remain.
- Specialty and biopharma expansion: Management expects double-digit revenue growth in specialty pharmaceuticals and biopharma solutions, supported by new commercial agreements, increased capacity for advanced therapies, and continued traction in MSO (management services organization) strategies for specialty practices.
- Margin initiatives and cost management: The company is executing operational simplification and cost optimization programs in its medical products business, aiming to offset pressure from rising input costs such as fuel and resin. Management noted that tariff tailwinds are expected to balance commodity cost headwinds, but prolonged geopolitical conflicts could shift profit outcomes to the lower end of guidance.
- M&A integration and scale: Recent acquisitions in diabetes supply and home care (Strive Medical and AdaptHealth’s diabetes business) are expected to accelerate profit growth in the at-Home Solutions segment, while ongoing investments in logistics and digital infrastructure should create additional synergies and scale across the business.
Catalysts in Upcoming Quarters
In the coming quarters, our analysts will be tracking (1) the pace of specialty and biopharma solutions growth, especially as newly integrated assets ramp up; (2) the impact of operational efficiency programs and automation on margins in the medical segment; and (3) the realization of synergy targets and profit improvement from at-Home Solutions and logistics. Updates on regulatory risk and input cost management will also be key signposts.
Cardinal Health currently trades at $241.71, up from $238.50 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).
Our Favorite Stocks Right Now
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.
